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THE aim of the present study was to investigate the
interrelationship of the kinin system, nitric oxide and
eicosanoids  in  the  acute  phase  of  antigen-induced
arthritis (AIA) in rabbits. The arthritis was induced in
immunized  rabbits  and  the  following  parameters
were evaluated 24 hours later: leukocyte influx (total
and differential white cell count), vascular permeabil-
ity  (Evans’s  blue  method),  and  synovial  PMN  cell
infiltrate. PGE2 and LTB4 (radioimmunoassay) levels
were  quantified  in  the  synovial  fluid.  The  animals
were pre-treated with 20 mg/kg/day during 14 days
with L-NAME or D-NAME and/or Enalapril (0.12 mg/
kg/day–14 days), and/or the B2 antagonist of Bradyki-
nin  HOE  140  (0.9 mg/kg).  Our  results  showed  that
L-NAME was effective in the prevention of AIA with
reduction of all inflammatory parameters analyzed.
Enalapril partially reverted  the L-NAME anti-inflam-
matory effects. The simultaneous treatment with HOE
140 abolished this reversion and returned the inflam-
matory parameters to the levels observed in L-NAME
treated  animals.  Our  results  suggest  that  pressoric
alterations induced by L-NAME could not account for
all  its  anti-inflammatory  action  in  this  model  of
experimental arthritis. Additionally the contribution
of the kinin system in AIA was characterized as well
as its interaction with eicosanoids and nitric oxide.
Key  words:  Experimental  arthritis,  Nitric  oxide,  Eicosa-
noids, Bradykinin
Introduction
Rheumatoid  arthritis  is  an  autoimmune  disease  in
which  chronic  inflammation  of  the  synovial  lining
cells produce pain, swelling and progressive erosion
of  the  synovial  joints.  Dumonde  &  Glynn1 first
described antigen-induced  arthritis  (AIA)  in  rabbits.
AIA evolves as a progressive immunological arthritis,
which  in  histopathological  terms  closely  resembles
rheumatoid arthritis in man. The acute phase of AIA is
a  typical Arthus  reaction  which  occurs  in  the  joint
with complement activation and polymorphonuclear
(PMN) leukocyte migration.2
Nitric oxide (NO) is  a  very  small and  ubiquitous
molecule synthesized from L-arginine by nitric oxide
synthases  (NOS).  NO  is  produced  in  the  joint  by
chondrocytes,3–6 synoviocytes6,7 and osteoblasts.6 It
has  been  involved  in  inflammatory  reactions  with
both pro and  anti-inflammatory properties. Endoge-
nous  release  of  NO  could  act  as  anti-inflammatory
through the reduction of leukocyte adhesion,8,9 and
inhibition  of  synthesis  of  cyclo-oxygenase  products
such  as  prostaglandin  E2 (PGE2),  thromboxane  B2
(TxB2)  and  interleukin-6  (IL-6).10 Endogenous  NO
has also been described as a pro-inflammatory mole-
cule  showing  interactions  with  cytokines11–13 and
inflammatory products of the cyclo-oxygenase path-
way.14–20 Studies  have  shown  that  NO  increases
interleukin-1b (IL-1) and eicosanoid products which
may result in  the exacerbation  of the inflammatory
response.12,13 The  participation  of  NO  in  intra-
articular inflammatory process has been fully descri-
bed  in  arthritic  patients.21,22 NOS  inhibitors  have
been widely used in studies of NO influence in the
inflammatory  process.  The  administration  of  NOS
inhibitors  in  the  experimental  arthritis  in  rats  was
followed by reduction in the intra-articular accumula-
tion of leukocytes, joint erosion, and paw swelling as
well  as  histopathological  abnormalities.23–27 Inhibi-
tion  of  NO  biosynthesis  by  L-arginine  antagonism
reduced  PGE2 production  by  condrocytes3 without
effect  upon  the  increased  production  of  PGE2 by
synoviocytes stimulated with IL-1.7 Moreover, endog-
enous release of NO enhances macrophage cycloox-
ygenase (COX) activity and increases the production
of  pro-inflammatory  prostaglandins.13,28 Several
studies suggest that NO participates in the inflamma-
tory response and joint destruction. Slices of rabbit
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following stimulation with human recombinant IL-1b .
Treatment of cartilage fragments with NOS inhibitor
decreased  NO  synthesis  stimulated  by  IL-1b and
restored proteoglycan synthesis.29 We previously ver-
ified that chronic treatment of arthritic rabbits with
L-NAME evoked reduction of the cellular influx and
protein leakage to the articular cavity. Additionally the
synovial fluid of these animals showed reduction  of
PGE2, IL1 and NO2/NO3 levels.30 Chronic administra-
tion of NOS inhibitors causes vasoconstriction with
potential  reduction  in  cell  migration. The  contribu-
tion  of  this  pressoric  alteration  evoked  by  chronic
treatment  with  L-NAME  to  its  anti-inflammatory
action as well as the possible links between NO and
other mediators of inflammatory reaction have so far
been  poorly  studied  in  the  articular  environment.
Thus, in the present study we analyzed the leukocyte
migration, protein leakage, synovium polymorphonu-
clear cell infiltrate and eicosanoids production in the
synovial fluid of knee joints of rabbits with AIA treated
with NOS inhibitor, Enalapril and the B2 antagonist of
Bradykinin HOE 140.
Material and methods
Induction of arthritis
The Animal  Ethics  Committee  of  COBEA  (Brazilian
College  of  Experimental Animals)  has  approved  all
experimental  procedures  performed  on  animals  in
accordance  with  procedures  set  by  UFAW  (The
Universities  Federation  for  Animals  Welfare).  Male
New  Zealand  White  rabbits  were  sensitized  with
5 mg of methylated bovine serum albumin (mBSA –
Sigma)  in  1 ml  Freund’s  complete  adjuvant  (Gibco)
and  1ml  of  sterile  saline  through  injections  at
subcutaneous and muscular sites in the suprascapu-
lar and gluteal regions, respectively. Seven days after
the  immunization  the  animal  was  once  a  week
boosted  with  intradermical  injection  of  1 mg/ml  of
mBSA. Then, cutaneous Arthus reaction characterized
by central necrosis was observed 24h later. Simulta-
neously, the serum antibody titles against mBSA were
quantified by immunodiffusion. The animals used in
the  experiment  were  those  who  appropriately
responded  to  the  second  cutaneous  challenge  and
have had anti-mBSA titles over 1/8. Seven days after
the third booster, arthritis was induced in the knee
joint by the injection of 0.5ml of a sterile solution of
mBSA  (2mg/ml)  into  the  articular  cavity. The  con-
tralateral joint was injected with saline. Twenty four
hours  after  intra-articular  challenge  the  animal  was
anaesthetized  with  a  mixture  of  xylazine  (5 mg/kg)
associated  with  ketamine  (50mg/kg)  by  intramus-
cular  injection  and  after  that  it  was  killed  by
intravenous injection of 2.0ml of KCI 20%.
Treatments
A  group  of  animals  was  randomly  treated  with
L-NAME (Sigma), a competitive NOS inhibitor, or its
inactive  form  D-NAME  (Sigma). The  dose  for  both
treatments was of 20mg/kg/day mixed with drinking
water. Drugs were administered for 2 weeks prior to
the induction of arthritis, and started simultaneously
with  the  second  booster. Another group of animals
was randomly treated with Enalapril, an angiotensin
converting  enzyme  (ACE),  which  produces  blood
pressure  decrease.  The  treatment  with  Enalapril
started simultaneously with L-NAME and the dose of
the  drug  was  0.12mg/kg/day  mixed  with  drinking
water.  The  B2  antagonist  of  Bradykinin  HOE  140
(D-Arg-[Hyp3, Thl5, Dtic 5, Oic 8]-bradykinin) was injec-
ted  subcutaneously  in  a  dose  of  0.3mg/kg  every  8
hours after the arthritis induction.
Sampling of synovial fluid
Immediately after the sacrifice 2ml of saline contain-
ing EDTA (1 mg/ml) was injected into the knee joint.
Synovial fluid was aspirated, the joint was opened and
the remainder of the synovial fluid as well as synovial
membrane was recovered. Total and differential leuko-
cyte count was done in a Neubauer chamber under
light microscopy. For the differential white cell count
smears were prepared from a cell pellet and stained
with Giemsa. The synovial fluid was stored at –70°C
for eicosanoids determination.
Assessment of vascular permeability response
with Evans’s blue dye
Before mBSA injection to induce arthritis the animals
received iv.  20mg/kg of Evans’s blue dye in a  2.5%
saline solution. The dye combines with the proteins of
the plasma giving rise to a tagged macromolecule that
passes  the  endothelial  barrier  only  to  a  negligible
extent under normal conditions, but it is deposited in
the tissues under circumstances of increased vascular
permeability. The synovial fluid was centrifuged and
the  optical  density  colorimetrically  assessed  at
630nm. The concentration of dye bound to protein in
the  synovial  fluid  was  estimated  from  a  standard
graph recording the optical density of serial dilution
of a known sample of Evans’s blue in NaCl. Results are
expressed as m g of protein/ml of synovial fluid.
Synovial membrane histology
After  sampling  the  synovial  fluid  and  opening  the
articular cavity, the synovial membrane was excised
and  sections  were  stained  with  hematoxylin  and
eosin for evaluation of PMN cell infiltrate under light
microscopy. The  synovium  PMN  cell  infiltrate  was
quantified  as  absent  or  rare,  mild,  or  severe  by  an
observer blinded to the experimental groups.
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PGE2 and  LTB4 levels  were  assayed  in  the  synovial
fluid  using  commercial  kits  (Amersham,  UK)  as
previously  described.31,32 The  radioimmunoassays
were  performed  in  polypropylene  tubes  with  the
reagents  diluted  in  phosphate-buffered  saline  with
gelatin and thimerosal. One hundred microliters each
of unknown samples, tracers (I125 PGE2 or H3 LTB4),
and  rabbit antiserum to each eicosanoid  were com-
bined  and  incubated  overnight  at  8°C  for  LTB4
determination and incubated for 2 hours at 25°C in a
water  bath  for  PGE2 determination.  Unbound  radi-
olabeled PGE2 was removed by the addition of 250 m l
of donkey anti-rabbit serum coated onto magnetizable
polymer particles, and LTB4 by the addition of 250 m l
of 2% charcoal suspension coated with 0.4% dextran
to the tubes. After centrifugation the residual bound
activity was measured in each tube by counting I125
PGE2 in a gamma scintillation counter and H3LTB4 in
a beta scintillation  counter. Cross reactivities of the
antiserum with other eicosanoids were below 0.05% .
The  assay  sensitivities  were  1.25  to  160pg/tube
(PGE2), and 1.6 to 200pg/tube (LTB4).
Statistics
Results are expressed as mean ± s.e.m.  The results were
analyzed by Student’s t test or by repeated measured
ANOVA and compared with student Newman Keuls
test. The chosen level of significance was 0.05.
Results
Leukocyte influx and vascular permeability in
the synovial fluid
To investigate the contribution of pressoric alteration
to  the  anti-inflammatory  properties  of  chronic
L-NAME  treatment,  leukocyte  influx  and  protein
leakage to the articular cavity was quantified in the
synovial  fluid  collected  from  animals  treated  with
L-NAME or D-NAME with or without Enalapril. Syno-
vial fluid cells and vascular permeability were meas-
ured 24 hours  after  articular  challenge  with  mBSA.
Panel A (Fig. 1) shows the effect of L-NAME compared
with  control  animals  in  the  reduction  of  cellular
migration to the inflamed area. The reduced migration
occurs mainly in the number of polymorphonuclear
(PMN) leukocytes, the central cell in the acute phase
of the inflammatory reaction, although mononuclear
(MN) cell migration was also affected. The simultane-
ous administration of Enalapril with L-NAME partially
restores  this  parameter. The  cellular  influx  to  the
articular  cavity  observed  in  animals  treated  with
Enalapril  alone  was  similar  to  that  observed  in  the
animals  treated  with  L-NAME  plus  Enalapril.  The
synovial fluid of the control joint, injected with saline
exhibited only resident cells (dotted line). Leukocyte
counts  in  the  articular  cavity  of  D-NAME  treated
animals  did  not  differ  from  the  leukocyte  count  in
control animals, which drank only water30.
The vascular  permeability  shown  in  panel B was
quantified  by  Evans’s  blue  method.  Our  results
showed a  significant  decrease in  protein  leakage to
the articular cavity in the synovial fluid collected from
L-NAME treated animals. The knee joint injected with
saline  showed  low  levels  of  dye  bound  to  protein.
Similar findings in the protein leakage to the articular
cavity were observed in both D-NAME treated animals
and  those  which  drank  only  water.  The  protein
leakage analyzed in the joint fluid of animals treated
with Enalapril or Enalapril plus L-NAME did not differ
from the control animals. In all groups evaluated the
synovial  membrane  PMN  cell  infiltrate  showed  a
similar pattern to the PMN infiltrate observed in the
synovial fluid (data not shown). In a previous paper
we  showed  that  the  synovial  membrane  of  animals
receiving mBSA intra-articularly had intense PMN cell
infiltrate  at  24  hours.  Treatment  with  the  NOS
inhibitor L-NAME, prior to the induction of arthritis,
greatly  reduced  the  cell  infiltration  in  the  synovial
membrane 24 hours after the induction of arthritis.30
Fig.  2,  Panels  A  and  B,  shows  the  inflammatory
parameters analyzed in  animals  simultaneously trea-
ted with the B2 antagonist of Bradykinin  HOE 140.
The cellular influx and the protein leakage analyzed in
the synovial fluid of these animals were remarkably
reduced when compared with the same parameters
observed in animals without HOE 140 treatment. It is
worth  noting  that  the  HOE  treatment  drastically
reduced  the  inflammatory  parameters  measured  in
the  synovial  fluid  of  L-NAME  plus  Enalapril  treated
animals. These  results  show  the  importance  of  the
kinin system in the development of AIA in rabbits.
Eicosanoids levels in the synovial fluid
The  synovial  fluid  of animals treated with  L-NAME,
D-NAME,  Enalapril  and  HOE140 was  collected,  and
the  eicosanoids  PGE2 and  LTB4 assayed  by  radio-
immunoassay. The results are shown in Figs 3 and 4
respectively. The PGE2 level was significantly reduced
with  L-NAME  treatment,  in  accordance  with  our
previous results.30 The simultaneous treatment with
Enalapril  completely  reverted  this  inhibition.  The
treatment  of  animals  with  HOE  140  drastically
reduced the level of PGE2 in all groups evaluated. It is
important to note that the same result even occurred
in  the group of  animals treated only with  Enalapril
plus  HOE  140. The  level  of  LTB4 shown  in  Fig.  4
exhibited  a  quite  different  pattern  of  alteration.
Although reduced after treatment with L-NAME alone
or  combined  with  Enalapril,  the  level  of  LTB4 was
reverted to that observed in control animals when the
treatment included HOE 140. Treatment with D-NAME
did not affect the synovial fluid levels of eicosanoids
Bradykinin involvement in induced NO and PGE2 production
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which drank only water.30
Discussion
Our previous results clearly implicate nitric oxide in
the IL-1 induced PGE2 production in the synovial fluid
of acute arthritis  in  rabbits.30 In  this study  we also
demonstrate  that  treatment  with  the  NOS  inhibitor
L-NAME  was  associated  with  a  reduction  in  some
signs of acute articular inflammation in rabbits such as
vascular  permeability  and  synovial  membrane  PMN
cell infiltrate. In the acute phase of AIA we noticed a
reduction in the number of leukocytes coming to the
inflamed  area.  This  finding  is  consistent  with  the
study  of  Belenky  et  al.,33 who  found  that  NOS
inhibitors attenuated chemotaxis of unstimulated and
primed PMN leukocytes. Kaplan et al.,34 using periph-
eral  human  neutrophils  incubated  with  the  NOS
inhibitor, LNMA, demonstrated a reduction of leuko-
cyte  chemotaxis  to  FMLP. This  inhibition  could  be
overcome if L-arginine or dibutyryl cGMP were added
together with the LNMA. These studies point out the
importance of NO in the direction of cell movement.
Our  results  clearly  show  that  under  inflammatory
challenge the migratory response of PMN cells and
the  synovium  PMN  cell  infiltrate  were  reduced  in
animals treated with L-NAME. This suggests that the
endothelial  lining of vessels within  the rabbit  syno-
vium may be an unusual microvascular network. We
hypothesized  that  chronic  treatment  with  an  NOS
inhibitor promotes vascular pressoric alteration that
could be account for its anti-inflammatory action. The
simultaneous treatment of these animals with Enala-
pril,  an  ACE  inhibitor,  restored  the  cellular  influx,
protein leakage and eicosanoids production almost to
the normal range observed in control arthritic joints.
BK induces increase in the blood flow of the rabbit
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248 Mediators of Inflammation · Vol 8 · 1999
FIG.  1.  Panel  A:  Total  and  differencial  cell  counts  (polymorphonuclear =  ;  mononuclear  =  ),  and  Panel  B:  Vascular
permeability (BSA injected joint = black columns; Saline injected = white columns) assessed in the joint fluid of rabbits with
24 hours of antigen-induced arthritis. The animals were treated before induction of arthritis with L-NAME (n = 16), Enalapril (n
= 11), L-NAME+Enalapril (n = 10) and compared with control animals (n = 20). The results expressed mean ±s.e.m.*<0.05.synovium via activation of B2 receptors.35 Then, we
also  analyzed  the  participation  of  the  kinin  system
through  co-administration  of  a  B2  antagonist  of  BK
HOE  140  to  the  animals,  before  and  during  the
arthritis  development.  This  treatment  promoted
remarkable reduction of cellular influx, protein leak-
age and PGE2 level in the synovial fluid. It is worth
noting that concomitant  administration  of HOE 140
completely  abolished the  increase of the  inflamma-
tory  parameters  promoted  by  Enalapril  to  L-NAME
treated animals.
NO  appears  to  be  generated  by  the  vascular
endothelial cells via constitutive NO synthase stimu-
lated  by  inflammatory  mediators  like  histamine,  5
hydroxytryptamine  and  Bradykinin  or  by  the  indu-
cible enzyme carried to the inflammatory site by PMN
cells.36 The  magnitude  in  the  reduction  of  the
inflammatory  parameters  observed  with  HOE  140
treatment  suggests  that  NO  generation  in  experi-
mental  arthritic joints follows BK  stimulation of B2
receptors. The results obtained in all animals treated
with the B2 antagonist of Bradykinin  irrespective of
other treatments were similar to the values observed
in animals treated only with L-NAME and included the
level of NO2/NO3 (data not shown). The only excep-
tion  was  in  the  level  of  LTB4 measured  in  the
experimental  joints  of  HOE  treated  animals,  which
result is compared with those obtained without HOE
treatment. This finding suggests a possible inhibitory
action of kinin system products in the lipooxygenase
pathway.
LTB4 would be considered a potent chemotactic in
the acute phase of inflammatory response.37We have
recently  found  that  LTB4 levels  decreased  in  the
synovial  fluid  of  untreated  animals  at  24  hours  of
arthritis  when  compared with  LTB4 levels  found  in
Bradykinin involvement in induced NO and PGE2 production
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FIG.  2.  Panel  A:  Total  and  differencial  cell  counts  (polymorphonuclear =  ;  mononuclear  =  ),  and  Panel  B:  Vascular
permeability (BSA injected joint = black column; Saline injected = white column) assessed in the joint fluid of rabbits with 24
hours of antigen-induced arthritis. The animals were treated before induction of arthritis with HOE 140 (n = 4), Enalapril + HOE
(n = 4), L-NAME + Enalapril + HOE (n = 4) The results expressed mean ±s.e.m.*<0.05. compared with mean of 20 control
animals.animals  at  4  hours  of  arthritis  (LTB)4 4th  h=
2.48±0.16ng/ml; LTB4 24th h  =  0.95±0.14ng/ml).38
The  reduced  levels  of LTB4 in  animals  treated  only
with Enalapril corroborate previous results in arthritic
patients  treated  for  arterial  hypertension  with ACE
inhibitors.39,40 The  reduced  levels  of  LTB4 and  the
impaired  migration  of  leukocytes  to  the  articular
cavity in L-NAME treated animals suggest that another
mediator apart, LTB4 possibly can be involved in the
cell attraction to the articular cavity in this phase of
AIA development.
The interactions between PGE2 IL-1 and NO synthe-
sis  have  been  related  in  many  studies.3,4,5,12,20,41
These studies show that  the endogenous release of
NO enhances COX activity  with further increase of
PGE2.  High  concentrations  of  PGE2 inhibited  NOS
expression and decreased NO synthesis.14 When NO
production was blocked by NOS inhibitors both NO
and  PGE2 simultaneously  decreased.12,16–19,25,28,42
NOS  inhibitors  also  block  cytokine  induced  release
of PGE.11,13 In these in vitro experiments NO seems
to  be  one  of  the  most  important  signals  in  the
activation  of cyclo-oxygenase  to  produce  PGE2. We
previously  found  that  inhibition  of  NO  production
with  L-arginine  antagonist  L-NAME  significantly
reduced IL-1b and PGE2 levels in the synovial fluid,
with  simultaneous  reduction  of  total  NO2/NO3 and
suppression  of AIA.30 In  this study  we verified that
treatment  with  an  ACE  inhibitor,  Enalapril,  was
efficient  in  the  reversion  of  inflammatory  para-
meters in the synovial fluid induced by NOS inhibi-
tion.  This  effect  may  not  be  in  consequence  of
arterial pressure normalization but due to Bradykinin
accumulation  at  the  site  of  injury  and  was  com-
pletely  blocked  by  administration  of  BK  antagonist
HOE  140.
Together  our  results  show  that  the  pressoric
mechanism  acting  in  chronic  administration  of
L-NAME  did  not  account  for  all  anti-inflammatory
properties of NOS inhibitors in the development of
F. A. S. Pal´ acios et al.
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FIG. 3. The striped column shows the PGE2 levels in the synovial fluid of animals treated with Enalapril (n = 7), L-NAME +
Enalapril (n = 7) and control animals (n = 10). The black column shows means of four animals submitted to the same treatments
and simultaneously injected with HOE 140. The results expressed mean ±s.e.m. *<0.05 compared with groups without HOE
140 treatment.
FIG. 4. The striped column shows the LTB4 levels in the synovial fluid of animals treated with Enalapril (n = 7), L-NAME +
Enalapril (n = 7) and control animals (n = 10). The black column shows means of four animals submitted to the same treatment
and simultaneously injected with HOE 140. The results expressed mean ±s.e.m. *<0.05 compared with control animals.AIA  in  rabbits.  Additionally  we  demonstrate  the
participation  of  Bradykinin  in  the  acute  phase  of
antigen-induced  arthritis  in  rabbits  as  well  as  the
interrelationship  of  the  kinin  system  with  NO  and
eicosanoids production in the arthritic joint.
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